Important Safety Information Prescribing Information This website is intended for US residents only.
Sancuso Logo

SANCUSO® (granisetron transdermal system) oncology nurse information

When to consider SANCUSO® (granisetron transdermal system)

Oncology nurses are the primary and best resource for patients to manage chemotherapy-induced nausea and vomiting (CINV)—identify the patients who might be suitable for SANCUSO

Do you recognize these patients?

Patients with previous breakthrough symptoms3,a,b

  • Patients may experience a decrease in therapeutic effect when drug plasma levels are low4
  • Repeated administration of oral medication, such as antiemetics, over several days can give rise to peaks and troughs in plasma drug levels5,a

Patients who are forgetful6,7

  • Patients may experience forgetfulness or cognitive impairment due to their chemotherapy regimen6
  • Forgetting to take a daily oral antiemetic may result in breakthrough nausea and vomiting7,b

Patients taking polypharmacy8

  • Poor treatment adherence may result due to complex treatment regimens8
  • The rate of adherence to medications decreases as the dosing frequency increases8

Patients receiving multiday chemotherapy3

  • Multiday regimens, which are often highly emetogenic, may result in consecutive periods of acute CINV3

How SANCUSO may be able to help

SANCUSO may be suitable for:

Sancuso can be considered for patients who have trouble swallowing

Patients who have difficulty swallowing

Patients may experience difficulty swallowing as a result of certain cancer types (eg, head and neck), or treatment regimens9

Combination radiation and chemotherapy may increase oral mucositis and difficulty swallowing

Patients receiving combination radiation/chemotherapyb

Combination radiation/chemotherapy contributes to oral mucositis and difficulty swallowing10

Sancuso may help patients with limited gut motility or absorption

Patients with limited gut motility/absorption

Malignancy-associated delayed gastric emptying may lead to changes in the absorption of orally administered drugs such as antiemetics11

Combination radiation and chemotherapy may increase the risk of oral mucositis

Patients with oral mucositis

The risk of oral mucositis increases with certain chemotherapeutic agents or combination radiation/chemotherapy10,b,c

When to consider SANCUSO

Download the flashcard to see when it might be appropriate to consider SANCUSO for your patients.


Request a sample

You may have patients with chemotherapy-induced nausea and vomiting (CINV) who are appropriate for SANCUSO. Request a sample at no cost to see if SANCUSO is the right option for your patients.

Request Sample

Connect to stay informed

You may have patients with CINV who are ready for SANCUSO. Now you can receive updates about SANCUSO and learn about new resources as they become available.

Stay Informed
  1. SANCUSO is not a rescue medication or indicated for breakthrough symptoms.1
  2. SANCUSO is not indicated for radiation-induced nausea and vomiting.1
  3. Patients with cancer who are mechanically compromised include those with oral and/or gastrointestinal impairment associated with chemotherapy, with or without radiation, or tumor burden, who may be unable to take or retain oral antiemetics.9,10
Indication and Important Safety Information


Sancuso® (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days.


Sancuso is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the transdermal system.


Adverse Reactions

The most common adverse reaction (≥ 3%) is constipation.

You are encouraged to report suspected adverse reactions to Cumberland Pharmaceuticals Inc. at 1-800-Sancuso or FDA at 1-800-FDA-1088 or

See full Prescribing Information for SANCUSO.

Verify all references:
  1. SANCUSO [package insert]. Bridgewater, NJ: Kyowa Kirin, Inc.; 2020.
  2. Schulmeister L. Granisetron transdermal system: a new option to help prevent chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs. 2009;13(6):711-714. doi:10.1188/09.CJON.711-714.
  3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Antiemesis. National Comprehensive Cancer Network. Updated July 20, 2011. Accessed December 18, 2019.
  4. Mason JW, Moon TE. Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management. Cancer Manag Res. 2013;5:179-185. doi:10.2147/CMAR.S34352.
  5. Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM; on behalf of the SANCUSO Study Group. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2011;19(10):1609-1617. doi:10.1007/s00520-010-0990-y.
  6. Chemo brain. American Cancer Society website. Updated June 9, 2016. Accessed December 18, 2019.
  7. Fujii H, Iihara H, Ishihara M, Takahashi T, Yoshida K, Itoh Y. Improvement of adherence to guidelines for antiemetic medication enhances emetic control in patients with colorectal cancer receiving chemotherapy of moderate emetic risk. Anticancer Res. 2013;33(12):5549-5556.
  8. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
  9. Raber-Durlacher JE, Brennan MT, Verdonck-de Leeuw IM, et al. Swallowing dysfunction in cancer patients. Support Care Cancer. 2012;20(3):433-443. doi:10.1007/s00520-011-1342-2.
  10. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120(10):1453-1461. doi:10.1002/cncr.28592.
  11. Keller J, Layer P. Intestinal and anorectal motility and functional disorders. Best Pract Res Clin Gastroenterol. 2009;23(3):407-423. doi:10.1016/j.bpg.2009.02.012.